All In Biotech

Drug Trial Radar · NCT05970640

A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease

Phase Ib Trial to Assess Safety and Tolerability of Multiple Subcutaneous Doses of BI 3006337 in Patients With Overweight or Obesity and Hepatic Steatosis

Last checked: Nov 20, 2026Latest source record: Dec 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

64

Actual

Start

Aug 14, 2023

Primary completion

Oct 31, 2024

Study completion Nov 7, 2024

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Aug 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with overweight or obesity who also have fatty liver disease. The purpose of this study is to find the highest dose of BI 3006337 that people with overweight or obesity and with fatty liver disease can tolerate. Participants are divided into 4 groups of equal size randomly, which means by chance. Different doses of BI 3006337 are given to participants in each group. Participants in each group receive an injection of either BI 3006337 or placebo once a week. Placebo injections look like BI 3006337 injections but do not contain any medicine. Participants are in the study for about 4 months. During this time, they visit the study site 18 times. Three of the visits include overnight stays at the study site. The doctors check the health of the participants and note any health problems that could have been caused by BI 3006337.

Conditions

  • Non-alcoholic Fatty Liver Disease
  • Obesity

Interventions

  • BI 3006337Drug

    Subject with overweight/obesity and steatosis received subcutaneous solution once weekly.

  • Placebo matching BI 3006337Drug

    Subject with overweight/obesity and steatosis received subcutaneous solution once weekly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Drug-related Adverse Events (AEs)Time frame: From drug administration of BI 3006337 until end of the treatment, up to 99 days

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Velocity Clinical Research-Chula Vista

    Chula Vista, California

  • Velocity Clinical Research-La Mesa-69117

    La Mesa, California

  • Catalina Research Institute, LLC-Montclair-49051

    Montclair, California

  • Accel Research Sites-Deland-67606

    DeLand, Florida

  • Floridian Clinical Research-Miami Lakes-68368

    Miami Lakes, Florida

  • iResearch Atlanta

    Decatur, Georgia

  • Centricity Research-Columbus-68879

    Columbus, Ohio

  • AMR Knoxville

    Knoxville, Tennessee

  • The Liver Institute at Methodist Dallas

    Dallas, Texas

  • American Research Corporation at the Texas Liver Institute

    San Antonio, Texas

  • Endeavor Clinical Trials

    San Antonio, Texas

  • Velocity Clinical Research-West Jordan-69043

    West Jordan, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.